Patient outcomes in KCNQ2 developmental and epileptic encephalopathy.

Grant Maclaine¹, Michele H Potashman², Deepshikha Pawar³, Sugandh Sharma⁴, Katja Rudell⁵, Jason Lerner², Vlad Coric², Anne T Berg⁶, John Millichap⁷, Gil L'Italien²

¹Biohaven Bioscience Ireland Ltd, Dublin, Ireland.

²Biohaven Pharmaceuticals, Inc., New Haven, CT, USA.

³Parexel International Ltd, Mohali, India.

⁴Parexel International Ltd, Chandigarh, India.

⁵COA Science, Parexel International, London, UK.

⁶Decoding Developmental Epilepsies, Washington, DC, USA.

⁷Precision Epilepsy PLLC, Chicago, IL, USA.

PubMed PMC DOI PDF

Abstract

The aim of this study was to review and summarize the literature describing clinically observed or caregiver-reported and patient-reported KCNQ2 developmental and epileptic encephalopathy (DEE) outcomes. Three online databases and selected congress proceedings were searched (August 2023). Case reports and series, observational studies, non-randomized and single-arm trials, and registries and datab…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.